# Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

> **NCT04900311** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 490 (estimated)

## Conditions studied

- HER2+ Early or Locally Advanced Breast Cancer

## Interventions

- **DRUG:** pyrotinib + trastuzumab + nab-paclitaxel
- **DRUG:** pertuzumab + trastuzumab + nab-paclitaxel

## Key facts

- **NCT ID:** NCT04900311
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 490 (ESTIMATED)
- **Last updated:** 2021-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04900311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04900311, "Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04900311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*